Results from a phase 1 placebo-controlled study of single and multiple doses of the investigational integrase inhibitor VH4524184 (VH-184) in 84 HIV negative individuals were presented in an oral presentation by ViiV at AIDS 2024.
Single doses ranged from 10 to 460 mg and multiple doses from 160 to 480 mg for 14 days and PK/food interactions were included.
Read the full report by Simon Collins, HIV i-Base here.
Source : HIV i-Base
Related HIV and Co-Infections News
-
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial
-
New data from EACS 2025 on quality of life and comorbidities in people with HIV
-
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.